Value Sense
HSCS
Heart Test Laboratories, Inc. (HSCS)
Last Price$2.95.0%
Market Cap$2,541.3M
Intrinsic value score
5/10
Good
Intrinsic value
$337.2
DCF value - $673.1 Relative value - $1.3
Undervalued
11,448.4%
LTM P/E
(333.3x)
Peer set median 34.6x
Discount rate
5.2%
HSCS
is 11,448.4% undervalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

HSCS Intrinsic value

Key Highlights:
Relative Value vs Current Share Price
As of Mar 11, 2025 HSCS Relative Value is $1.2, which is overvalued by 57.3%, compared to current share price of $2.9.
DCF Value vs Current Share Price
As of Mar 11, 2025 HSCS DCF Value is $639.5, which is undervalued by 21,799.3%, compared to current share price of $2.9.
Methodology
Price per share, $
HSCS
Intrinsic value$337.2
Undervalued by11,448.4%
Current share price
2.9
Relative value
1.2
DCF value
639.5

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

HSCS Historical Intrinsic Value

Crunching data... Almost there!

HSCS vs Peer Set: Intrinsic Value Comparison

General

Intrinsic Value

Financials

Company name

Undervaluation/Overvaluation

Revenue growth

EPS growth

Net income margin

Heart Test Laboratories, Inc. logo
Heart Test Laboratories, Inc.HSCS
11,448.4%
261.2%
(99.7%)
(35,511.9%)
Median Peer Set
4.2%
59.2%
12.5%
Boston Scientific Corporation logo
Boston Scientific CorporationBSX
(61.9%)
17.6%
16.7%
11.1%
Insulet Corporation logo
Insulet CorporationPODD
(57.3%)
22.1%
101.7%
20.2%
DexCom, Inc. logo
DexCom, Inc.DXCM
(43.9%)
11.3%
(1.4%)
14.3%
Edwards Lifesciences Corporation logo
Edwards Lifesciences CorporationEW
(20.8%)
(9.4%)
202.2%
76.7%
Stryker Corporation logo
Stryker CorporationSYK
(17.8%)
10.2%
(5.8%)
13.2%
STERIS plc logo
STERIS plcSTE
(14.6%)
3.6%
257.9%
7.4%
Medtronic plc logo
Medtronic plcMDT
25.6%
3.6%
(2.1%)
11.4%
Abbott Laboratories logo
Abbott LaboratoriesABT
34.3%
4.6%
134.5%
31.9%
Zimmer Biomet Holdings, Inc. logo
Zimmer Biomet Holdings, Inc.ZBH
66.6%
3.8%
(9.4%)
11.8%
Koninklijke Philips N.V. logo
Koninklijke Philips N.V.PHG
159.4%
(0.8%)
122.5%
(3.9%)

Explore more intrinsic value tools hub for HSCS

Peter Lynch Fair Value
Intrinsic Value
Earnings Power Value
Ben Graham Fair Value
Earnings growth model
DCF value calculator
Discount rate
Peter Lynch charts
Reverse DCF
Relative Value

FAQ

What is Heart Test Laboratories, Inc. intrinsic value?

As of Mar 11, 2025, Heart Test Laboratories, Inc. Intrinsic Value is $337.2. This suggests it may be undervalued by 11,448.4% compared to its current price of around $2.9.

What is Heart Test Laboratories, Inc. DCF (discounted cash flow) valuation?

As of Mar 11, 2025, Heart Test Laboratories, Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at $639.5. This suggests it may be overvalued by 21,799.3% to its current price of around $2.9, using a discount rate of 5.2% and terminal growth rate of 3.0%.

Is Heart Test Laboratories, Inc. overvalued or undervalued?

Heart Test Laboratories, Inc. is currently considered undervalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $337.2, compared to a market price of around $2.9. This suggests a potential undervaluation of 11,448.4%.